Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Abstract We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy, and polypoidal choroidal neovasculopa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Keiichiro Tanaka, Yasuharu Oguchi, Tomoko Omori, Yumi Ishida, Hiroaki Shintake, Ryutaro Tomita, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, Kanako Itagaki, Akira Ojima, Takeshi Machida, Hideharu Sekine, Tetsuju Sekiryu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/328cde84e0ef45edaf7b4ea496f21095
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:328cde84e0ef45edaf7b4ea496f21095
record_format	dspace
spelling	oai:doaj.org-article:328cde84e0ef45edaf7b4ea496f210952021-12-02T18:27:48ZChanges in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease10.1038/s41598-021-87340-62045-2322https://doaj.org/article/328cde84e0ef45edaf7b4ea496f210952021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87340-6https://doaj.org/toc/2045-2322Abstract We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy, and polypoidal choroidal neovasculopathy. We measured the concentrations of the complement activation products (C3a, C4a), VEGF, and monocyte chemotactic protein-1 in the aqueous humor during intravitreal anti-VEGF injections for CNV. The VEGF level decreased significantly (P < 0.001), while the C3a and C4a levels increased significantly (P < 0.001 for both comparisons) 1 month after two monthly anti-VEGF injections. The VEGF level was correlated with the C3a (R = 0.328, P = 0.007) and C4a (R = − 0.237, P = 0.055) levels at baseline, but the correlation between the VEGF and C3a levels (R = − 0.148, P = 0.242) changed significantly (P = 0.028 by analysis of covariance) after anti-VEGF treatment. The C3a increase after anti-VEGF therapy did not change the visual outcomes in eyes with CNV for 1 year. Dysregulation of the complement system can be induced after anti-VEGF therapy.Keiichiro TanakaYasuharu OguchiTomoko OmoriYumi IshidaHiroaki ShintakeRyutaro TomitaAkihito KasaiMasashi OgasawaraYukinori SuganoKanako ItagakiAkira OjimaTakeshi MachidaHideharu SekineTetsuju SekiryuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Keiichiro Tanaka Yasuharu Oguchi Tomoko Omori Yumi Ishida Hiroaki Shintake Ryutaro Tomita Akihito Kasai Masashi Ogasawara Yukinori Sugano Kanako Itagaki Akira Ojima Takeshi Machida Hideharu Sekine Tetsuju Sekiryu Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
description	Abstract We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy, and polypoidal choroidal neovasculopathy. We measured the concentrations of the complement activation products (C3a, C4a), VEGF, and monocyte chemotactic protein-1 in the aqueous humor during intravitreal anti-VEGF injections for CNV. The VEGF level decreased significantly (P < 0.001), while the C3a and C4a levels increased significantly (P < 0.001 for both comparisons) 1 month after two monthly anti-VEGF injections. The VEGF level was correlated with the C3a (R = 0.328, P = 0.007) and C4a (R = − 0.237, P = 0.055) levels at baseline, but the correlation between the VEGF and C3a levels (R = − 0.148, P = 0.242) changed significantly (P = 0.028 by analysis of covariance) after anti-VEGF treatment. The C3a increase after anti-VEGF therapy did not change the visual outcomes in eyes with CNV for 1 year. Dysregulation of the complement system can be induced after anti-VEGF therapy.
format	article
author	Keiichiro Tanaka Yasuharu Oguchi Tomoko Omori Yumi Ishida Hiroaki Shintake Ryutaro Tomita Akihito Kasai Masashi Ogasawara Yukinori Sugano Kanako Itagaki Akira Ojima Takeshi Machida Hideharu Sekine Tetsuju Sekiryu
author_facet	Keiichiro Tanaka Yasuharu Oguchi Tomoko Omori Yumi Ishida Hiroaki Shintake Ryutaro Tomita Akihito Kasai Masashi Ogasawara Yukinori Sugano Kanako Itagaki Akira Ojima Takeshi Machida Hideharu Sekine Tetsuju Sekiryu
author_sort	Keiichiro Tanaka
title	Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
title_short	Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
title_full	Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
title_fullStr	Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
title_full_unstemmed	Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
title_sort	changes in complement activation products after anti-vegf injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/328cde84e0ef45edaf7b4ea496f21095
work_keys_str_mv	AT keiichirotanaka changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT yasuharuoguchi changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT tomokoomori changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT yumiishida changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT hiroakishintake changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT ryutarotomita changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT akihitokasai changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT masashiogasawara changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT yukinorisugano changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT kanakoitagaki changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT akiraojima changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT takeshimachida changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT hideharusekine changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease AT tetsujusekiryu changesincomplementactivationproductsafterantivegfinjectionforchoroidalneovascularizationinagerelatedmaculardegenerationandpachychoroiddisease
_version_	1718378031407431680

Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Ejemplares similares